Positive results for lung cancer study
Fucoidan is recognised for its potential anti-cancer properties. An extensive body of research has been undertaken in this area, with scientists suggesting that fucoidan may increase patient wellbeing as well as assisting in the treatment of the disease itself. The potential for fucoidan as an anti-cancer agent is explored in several review publications, including those by Fitton (2015), Kwak (2014) and Lowenthal (2014). A wide variety of cancer models have been utilised including blood, ovarian, breast, prostate, liver and head and neck cancers.
A recently published study investigated the potential effects of different concentrations of fucoidan on non-small cell lung cancer (NSCLC) cell lines in vitro. NSCLC is the most common type of lung cancer, accounting for approximately 85% of lung cancer cases globally.
The study investigated the anti-tumour effects of different concentrations of fucoidan in cell-based assays. In vivo investigations also examined how the consumption of fucoidan may influence the size and volume of a tumour in a mouse xenograft model.
The results showed that fucoidan inhibited the proliferation of the NSCLC cell lines and promoted cell death. Mice that were fed fucoidan exhibited significant reductions in both tumour volumes and weights. Researchers concluded that fucoidan conveyed anti-tumour effects and holds promising potential as a therapeutic agent for NSCLC.
The full paper, ‘Antitumor effect and molecular mechanism of fucoidan in NSCLC’ is published in the journal BMC Complementary Medicine and Therapies.